A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

NCT01589718 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No patients were enrolled

Conditions

Proliferative Diabetic Retinopathy

Interventions

DRUG: Macugen
DRUG: Sham

Sponsor

Greater Houston Retina Research